GLPwatch
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.
Ann Pediatr Endocrinol Metab · 2017
Last updated 2026-05-28GLP-1 is a hormone that helps control blood sugar by increasing insulin release from the pancreas while keeping the risk of low blood sugar low. Since natural GLP-1 breaks down quickly in the body, scientists developed longer-lasting versions called GLP-1 receptor agonists, such as exenatide and dulaglutide, which come in different dosing options for patients.
AI summary of the abstract below.
| Journal | Ann Pediatr Endocrinol Metab, 2017 |
|---|---|
| Citations | 50 |
| Relative citation ratio | 2.05 |
| NIH percentile | 74 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic β-cell insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D.
Verbatim abstract via PubMed 28443255 ↗